Sagimet Biosciences (STU:0O2) Ending Cash Position: €31.68 Mil (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Ending Cash Position?

Sagimet Biosciences STU:0O2 +1.66% 10 Ending Cash Position is €31.68 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Sagimet Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 was €31.68 Mil.

Sagimet Biosciences's quarterly Ending Cash Position increased from Sep. 2025 (€27.69 Mil) to Dec. 2025 (€29.91 Mil) and increased from Dec. 2025 (€29.91 Mil) to Mar. 2026 (€31.68 Mil).

Sagimet Biosciences's annual Ending Cash Position increased from Dec. 2023 (€68.90 Mil) to Dec. 2024 (€72.43 Mil) but then declined from Dec. 2024 (€72.43 Mil) to Dec. 2025 (€29.91 Mil).

Sagimet Biosciences Ending Cash Position Related Terms

Sagimet Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Ending Cash Position Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 50.21 0.15 68.90 72.43 29.91

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.86 36.70 27.69 29.91 31.68
STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sagimet Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=64.767+-34.859
=29.91

Sagimet Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=30.293+1.388
=31.68

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €31.68 Mil mean?
Sagimet Biosciences (STU:0O2) has a Ending Cash Position of €31.68 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Ending Cash Position too high?
Sagimet Biosciences' current Ending Cash Position is €31.68 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Ending Cash Position compare to EDIT and AUTL?
Sagimet Biosciences' Ending Cash Position of €31.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Ending Cash Position is €31.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Ending Cash Position of €31.68 Mil. The current Ending Cash Position is €31.68 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Ending Cash Position is €31.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price